Tumor oxygenation

Tumor oxygenation refers to the level of molecular oxygen present within a solid tumor. It is not a discrete molecule or receptor but rather a physiological property that reflects how much oxygen is available in the tumor microenvironment. Poorly organized and dysfunctional blood vessels within tumors often result in regions with low oxygen tension—a state known as "tumor hypoxia"—which can be defined as partial pressures of O₂ below 10 mm Hg[6]. This condition arises because rapidly growing tumors outpace their blood supply, leading to areas where cells are deprived of adequate oxygen. Hypoxic conditions within tumors have profound biological effects. They drive malignant progression, increase resistance to therapies such as radiation and some chemotherapies, promote metastasis, and alter cellular metabolism through activation of pathways like those controlled by HIFs (hypoxia-inducible factors)[1][5][6]. These adaptations allow cancer cells not only to survive but also become more aggressive. Tumor hypoxia is recognized as a major obstacle for effective cancer treatment; it reduces the efficacy of radiotherapy due to decreased formation and fixation of DNA-damaging radicals in low-O₂ environments ("oxygen enhancement effect")[3]. As such, assessing tumor oxygenation has been proposed as an important prognostic tool for predicting patient outcomes during therapy. However, there are currently no standardized clinical methods for routine measurement or targeting "tumor oxygenation" directly—therapeutic strategies instead focus on modifying its downstream effects or improving vascular function. Because "tumor oxygenation" describes a physiological state rather than a specific molecular entity or druggable target like an enzyme or receptor, it should not be considered a canonical therapeutic target itself. Instead, it represents an important aspect influencing many true molecular targets involved in cancer biology and therapy response[1][5][6]. In summary: **Tumor oxygenation** is not itself a molecule/receptor/target but rather describes the amount/distribution of O₂ within tumors—a critical determinant for cancer progression and treatment response. The term should be used carefully when structuring data about drug targets; related actionable targets include HIFs and angiogenic factors such as VEGF.

Other names

Tumor hypoxiaOxygenation status of tumorTumor pO₂Hypoxic tumor microenvironment

Drugs may target the consequences of low oxygen by inhibiting angiogenesis or blocking hypoxia-inducible factor (HIF) pathways[5].